Horizon Discovery
Financials
Estimates*
EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2022 |
---|---|---|---|---|---|---|---|
Revenues | 29.0m | 73.0m | 132m | 154m | 185m | 196m | - |
% growth | - | 152 % | 81 % | 17 % | 21 % | 6 % | - |
EBITDA | (7.9m) | (10.0m) | (10.0m) | (40.0m) | (7.0m) | (14.4m) | (3.1m) |
% EBITDA margin | (27 %) | (14 %) | (8 %) | (26 %) | (4 %) | (7 %) | - |
Profit | - | 7.0m | 30.0m | 48.2m | 60.9m | 65.5m | - |
% profit margin | - | 10 % | 23 % | 31 % | 33 % | 33 % | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$300k | Seed | ||
N/A | Grant | ||
$9.8m | Series A | ||
€300k | Grant | ||
N/A | £7.0m | Series B | |
$18.6m | Series C | ||
N/A | Support Program | ||
£6.9m | Series C | ||
N/A | £68.6m | IPO | |
$383m Valuation: $383m 1.9x EV/LTM Revenues -49.7x EV/LTM EBITDA | Acquisition | ||
Total Funding | €43.1m |
Recent News about Horizon Discovery
EditHorizon Discovery specializes in gene editing and gene modulation technologies, serving academic institutions, pharmaceutical companies, biotechnology firms, and clinical diagnostic laboratories. The company operates in the life sciences market, providing tools and services that help identify genetic drivers of human diseases, develop diagnostic workflows, and create new therapies for precision medicine. Horizon Discovery's business model revolves around offering innovative products such as CRISPR design tools, siRNA, and custom RNA synthesis, as well as services like cell line engineering and in vivo screening. Revenue is generated through the sale of these products and services, catering to clients who require advanced genetic research capabilities.
Keywords: gene editing, gene modulation, CRISPR, siRNA, RNA synthesis, cell lines, precision medicine, biotechnology, diagnostics, life sciences.